Rosemont Deal Shows Value Is Out There For US Exit, Perrigo Says
Planned Separation ‘Will Take Some Time’
Executive Summary
Perrigo management provided colorful commentary on Perrigo’s latest endeavors to separate the company’s US generics business, following the recent sale of Perrigo’s Rosemont Pharmaceuticals subsidiary for an “attractive” multiple.
You may also be interested in...
Perrigo Reaches $1.5bn Deal With Altaris For Rx Business
Perrigo has finally found the right deal to secure the long-awaited divestment of its prescription business, reaching an agreement worth just over $1.5bn with private equity firm Altaris Capital Partners.
COVID-19 Alters But Doesn’t Change M&A Machine In 2020
Mergers and acquisitions have long been a tool for value creation in the generics and biosimilars space. Even with the entire life sciences sector overwhelmed by the novel coronavirus pandemic, deals big and small continued in 2020.
Perrigo Writes Off $202m Of Value Amid ProAir Recall And Relaunch Uncertainty
Perrigo remains unable to say exactly when it will be able to relaunch its generic to Teva’s ProAir, a position that has left the company with no choice but to impair significantly the value of the asset in the firm’s financial third quarter.